Pliant Therapeutics Valuation
| PLRX Stock | USD 3.04 0.25 7.60% |
At this time, the company appears to be undervalued. Pliant Therapeutics holds a recent Real Value of $12.3 per share. The prevailing price of the company is $3.04. Our model determines the value of Pliant Therapeutics from analyzing the company fundamentals such as Shares Outstanding of 60.85 M, return on equity of -0.48, and Shares Owned By Institutions of 96.71 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pliant Therapeutics' valuation include:
Price Book 0.5349 | Enterprise Value | Enterprise Value Ebitda (2.54) | Price Sales 3.1 K | Enterprise Value Revenue 1.4 K |
Undervalued
Today
Please note that Pliant Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Pliant Therapeutics is based on 3 months time horizon. Increasing Pliant Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pliant Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pliant Stock. However, Pliant Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.04 | Real 12.3 | Target 40.18 | Hype 3.66 |
The intrinsic value of Pliant Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pliant Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pliant Therapeutics helps investors to forecast how Pliant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pliant Therapeutics more accurately as focusing exclusively on Pliant Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pliant Therapeutics' intrinsic value based on its ongoing forecasts of Pliant Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pliant Therapeutics' closest peers.
Pliant Therapeutics Cash |
|
Pliant Valuation Trend
Analysing the historical paterns of Pliant Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Pliant Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Pliant Therapeutics Total Value Analysis
Pliant Therapeutics is at this time projected to have valuation of (159.3 M) with market capitalization of 184.99 M, debt of 11.37 M, and cash on hands of 163.6 M. The negative valuation of Pliant Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Pliant Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(159.3 M) | 184.99 M | 11.37 M | 163.6 M |
Pliant Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pliant Therapeutics has an asset utilization ratio of 0.31 percent. This suggests that the Company is making $0.003085 for each dollar of assets. An increasing asset utilization means that Pliant Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Pliant Therapeutics Ownership Allocation
The majority of Pliant Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pliant Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pliant Therapeutics. Please pay attention to any change in the institutional holdings of Pliant Therapeutics as this could imply that something significant has changed or is about to change at the company.Pliant Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.58 M. Net Loss for the year was (161.34 M) with profit before overhead, payroll, taxes, and interest of 0.About Pliant Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Pliant Therapeutics. We calculate exposure to Pliant Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pliant Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.4 M | 1.4 M | |
| Pretax Profit Margin | (117.43) | (111.56) | |
| Operating Profit Margin | (134.03) | (127.33) | |
| Net Loss | (117.43) | (111.56) | |
| Gross Profit Margin | 0.56 | 0.48 |
Pliant Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 58.7 M |
Pliant Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Pliant Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Pliant we look at many different elements of the entity such as Pliant's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pliant Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pliant Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pliant Therapeutics' worth.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.